Transaction · 0001437749-26-004126

Stengone Carmine N.

Stengone Carmine N., CEO, PRES, reported an open-market or private sale at Contineum Therapeutics, Inc. involving 400.000000 shares for an estimated $6400.00. Reported holdings after the transaction were 14954.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCEO, PRES
CTNMContineum Therapeutics, Inc.
Filing timeFeb 13
Trade dateFeb 11, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$14.44
Pre-filing
1mo ago -36.5%1w ago +2.5%1d ago +9.1%
Returns since
7d +7.9%30d -10.0%90d -1.6%180d +3.7%1y +16.7%

CTNM price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CTNM since 2026-02-13Filed 208 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001437749-26-004126
Class A Common Stock
Transaction date
Feb 11, 2026
Filed Feb 13, 2026, 09:27 PM · 2d delay
Shares
400 sh
$1.60k per share
Estimated value
-$640k
Computed from shares × price
Holdings after
14.9k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO and President

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

  2. F2

    Includes 1,246 shares purchased through Issuer's Employee Stock Purchase Plan on November 15, 2024 and 2,096 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2025.

  3. F3

    The stock options are fully vested and exercisable.

Original filing · 0001437749-26-004126
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CTNM